Results from the Phase 2 ROSETTA Lung-02 study p suggest that pumitamig, an experimental bispecific antibody targeting PD-L1 and VEGF-A, may be a promising first-line treatment for patients with advanced non–small cell lung cancer (NSCLC) when combined with chemotherapy.
Among 40 patients enrolled in the study, the treatment achieved a 100% confirmed disease control rate. The confirmed overall response rate was 62.5%, while the unconfirmed response rate reached 72.5%. Responses were observed in both squamous and nonsquamous forms of NSCLC, with some patients achieving complete tumor responses.
The therapy also showed activity across all PD-L1 expression levels, including patients with little or no PD-L1 expression, a group that is often difficult to treat. In addition, most patients experienced major reductions in circulating tumor DNA, indicating deep antitumor activity.
The treatment’s safety profile was considered manageable. Serious treatment-related side effects occurred in about half of patients, but severe VEGF-related complications were uncommon, and no new safety concerns were identified.
Based on these encouraging results, pumitamig plus chemotherapy is advancing to a global Phase 3 trial, where it will be compared directly with the current standard of care.